Cash and cash equivalents

DGAP-News: Softing AG: Interim Statement on the 1st Quarter of 2021

Retrieved on: 
Tuesday, May 4, 2021
Asset, Cash, Cash and cash equivalents, Receivables, Nas, Musicians, Businesspeople

Cash and cash equivalents amounted to EUR 12.6 million on 31 March 2021, while current trade receivables also totaled EUR 12.5 million.

Key Points: 
  • Cash and cash equivalents amounted to EUR 12.6 million on 31 March 2021, while current trade receivables also totaled EUR 12.5 million.
  • Other significant amounts for the enhancement of existing products were expensed.\nAs of March 31, 2021, the Softing Group had 392 employees (previous year: 404).
  • In general, the same accounting policies were applied in the quarterly management statement as of March 31, 2021 as in the consolidated financial statements for the 2020 financial year.
  • This quarterly management statement was prepared without an auditor\'s review.\nAs of March 31, 2021, no changes occurred in the basis of consolidation of Softing AG compared to December 31, 2020.\n'

Kinsale Capital Group, Inc. Reports 2021 First Quarter Results

Retrieved on: 
Thursday, April 29, 2021
Money, Finance, Economy, Financial ratios, Investment, Financial markets, Mathematical finance, Rate of return, Cash and cash equivalents

b'The Company\xe2\x80\x99s net investment income was $6.9 million in the first quarter of 2021 compared to $6.0 million in the first quarter of 2020, an increase of 16.5%.

Key Points: 
  • b'The Company\xe2\x80\x99s net investment income was $6.9 million in the first quarter of 2021 compared to $6.0 million in the first quarter of 2020, an increase of 16.5%.
  • The Company\xe2\x80\x99s investment portfolio, excluding cash and cash equivalents, had an annualized gross investment return(5) of 2.6% for the first quarter of 2021 compared to 2.9% for the first quarter of 2020.
  • The weighted average duration of the fixed-maturity investment portfolio, including cash equivalents, was 4.3 years at March\xc2\xa031, 2021 and December\xc2\xa031, 2020.
  • Net operating earnings and percentages or calculations using net operating earnings (e.g., diluted operating earnings per share and annualized operating return on equity) are non-GAAP financial measures.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, April 29, 2021
Asset, Medical specialties, Cash, Cash and cash equivalents, Adenosine, XC2, Clinical medicine, Drugs

In addition to blocking the production of adenosine, CPI-006 has demonstrated activation of B cells.

Key Points: 
  • In addition to blocking the production of adenosine, CPI-006 has demonstrated activation of B cells.
  • The Company is also efficiently advancing its other clinical programs, CPI-818 and ciforadenant, along with pre-clinical programs in its pipeline.
  • Tumor biopsies will be evaluated for expression of the adenosine gene signature.\nAs of March 31, 2021, Corvus had cash, cash equivalents and marketable securities totaling $68.0\xc2\xa0million.
  • Angel Pharmaceuticals was launched through a collaboration with U.S.-based Corvus Pharmaceuticals and investments from investors in China.

Territorial Bancorp Inc. Announces First Quarter 2021 Results

Retrieved on: 
Thursday, April 29, 2021
Geography of Hawaii, Geography of the United States, Regions of the United States, Goldman Sachs, Subprime mortgage crisis, Honolulu, Hawaii, Cash and cash equivalents

Total interest income was $15.11 million for the three months ended March 31, 2021 compared to $18.58 million for the three months ended March 31, 2020.

Key Points: 
  • Total interest income was $15.11 million for the three months ended March 31, 2021 compared to $18.58 million for the three months ended March 31, 2020.
  • Investment securities increased by $48.40 million to $296.03 million at March 31, 2021 from $247.64 million at December 31, 2020.
  • Cash and cash equivalents increased to $410.79 million at March 31, 2021 from $363.54 million at December 31, 2020.
  • Territorial Savings Bank conducts business from its headquarters in Honolulu, Hawaii and has 29 branch offices in the state of Hawaii.

Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, April 28, 2021
Communication, Forward-looking statement, Economy, Articles, Money, Cash and cash equivalents, Short, Vikings

Pending the results, we expect to initiate a Phase 1b study of VK0214 in X-ALD patients this summer.

Key Points: 
  • Pending the results, we expect to initiate a Phase 1b study of VK0214 in X-ALD patients this summer.
  • Viking completed the first quarter of 2021 with$241.7 millionin cash, cash equivalents and short-term investments.\nUpcoming investor events.
  • Follow Viking on Twitter @Viking_VKTX.\nThis press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S.
  • Viking disclaims any obligation to update these forward-looking statements except as required by law.\n'

Nexon Purchases $100 Million Worth of Bitcoin

Retrieved on: 
Wednesday, April 28, 2021
Entertainment, Technology, Other Technology, Online, Mobile Entertainment, Electronic Games, Payment systems, Bitcoin, Cryptocurrencies, Digital currencies, Chaebol, Nexon, Currency, Money, Cash and cash equivalents

b'NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the purchase of 1,717 bitcoins for approximately $100 million (\xc2\xa511.1 billion) at an average price of approximately $58,226 (\xc2\xa56,446,183) per bitcoin, inclusive of fees and expenses.

Key Points: 
  • b'NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the purchase of 1,717 bitcoins for approximately $100 million (\xc2\xa511.1 billion) at an average price of approximately $58,226 (\xc2\xa56,446,183) per bitcoin, inclusive of fees and expenses.
  • This purchase represents less than 2% of Nexon\xe2\x80\x99s total cash and cash equivalents on hand1.\n\xe2\x80\x9cOur purchase of bitcoin reflects a disciplined strategy for protecting shareholder value and for maintaining the purchasing power of our cash assets,\xe2\x80\x9d said Owen Mahoney, President and CEO of Nexon.
  • \xe2\x80\x9cIn the current economic environment, we believe bitcoin offers long-term stability and liquidity while maintaining the value of our cash for future investments.\xe2\x80\x9d\nFounded in 1994, NEXON Co., Ltd. (Nexon) (3659.TO) is a company engaged in the production, development and operation of online games and Virtual Worlds.
  • Nexon currently has more than 50 live games on multiple platforms including mobile and available in more than 190 countries.

Sonor Investments Limited Reports Financial Results for the Year Ended December 31, 2020 and Three Months Ended March 31, 2021

Retrieved on: 
Tuesday, April 27, 2021
Money, Economy, Articles, Asset, Finance, Cash and cash equivalents, Investment, Dividend, Money, Economy, Articles, Asset, Finance, Cash and cash equivalents, Investment, Dividend

b'Michael Gardiner, Chairman and CEO stated that as at March 31, 2021, the Company\xe2\x80\x99s assets totaled $67.8 million compared to $66.8 million as at December 31, 2020.

Key Points: 
  • b'Michael Gardiner, Chairman and CEO stated that as at March 31, 2021, the Company\xe2\x80\x99s assets totaled $67.8 million compared to $66.8 million as at December 31, 2020.
  • These assets as at March 31, 2021 included $16.8 million of marketable securities, $35.6 million in a private investment and $15.4 million of cash and cash equivalents.\nDuring the year ended December 31, 2020, the Company realized $106,000 in net capital gains on the sale of investments and recorded no impairments on its security investments.
  • This compares to net capital gains of $243,000 on the sale of investments during the year ended December 31, 2019.
  • The dividend will be paid to shareholders of record at the close of business on September 1, 2021.\nSonor Investments Limited is an investment company located in Toronto, Canada.

ADVA posts strongest Q1 results in company’s history

Retrieved on: 
Thursday, April 22, 2021
Technology, Professional services, Security, Telecommunications, Software, Networks, Internet, Mobile, Wireless, Hardware, Finance, Electronic design automation, Asset, Cash, Cash and cash equivalents

Orders for network synchronization technology again developed positively in Q1.

Key Points: 
  • Orders for network synchronization technology again developed positively in Q1.
  • Hence the pro forma operating margin was at the top end of the guidance corridor of 7% to 9%.
  • Year-over-year cash and cash equivalents substantially increased by EUR 26.3 million from EUR 52.7 million at the end of Q1 2020.
  • With that, we have made an excellent start to the new financial year,\xe2\x80\x9d said Uli Dopfer, CFO, ADVA.

HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results

Retrieved on: 
Monday, April 5, 2021
Asset, Cash, Cash and cash equivalents

TUCSON, Ariz., April 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2021.

Key Points: 
  • TUCSON, Ariz., April 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2021.
  • HTG expects to report unaudited total revenue for the first quarter ended March 31, 2021 of approximately $1.4 million, and cash, cash equivalents and short-term marketable securities of approximately $30.8 million as of March 31, 2021.
  • In addition, these preliminary results are not a comprehensive statement of the companys financial results for the quarter ended March 31, 2021, should not be viewed as a substitute for complete financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the companys results for any future period.
  • The company expects to announce full March 31, 2021 financial results in advance of its quarterly conference call in May 2021.

NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates

Retrieved on: 
Wednesday, March 31, 2021
Asset, Cash, Cash and cash equivalents, Initial public offering, Carmer

2020 was a transformational year for NexImmune, said Scott Carmer, Chief Executive Officer.

Key Points: 
  • 2020 was a transformational year for NexImmune, said Scott Carmer, Chief Executive Officer.
  • On February 17, 2021, NexImmune completed a successful IPO and raised gross proceeds of $126M.
  • Cash and cash equivalents for the company as of December 31, 2020 were $5.0M, compared to $9.1M at December 31, 2019.
  • Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements.